# US 2014/0275055 A1 · Protein Kinase C Inhibitors and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0275055 A1
- Document ID: US20140275055A1
- Status: Published application
- Kind: A1
- Application number: 14/209,997
- Filed: 2014-03-13
- Published: 2014-09-18
- Earliest claimed: 2013-03-14
- Assignees: Rigel Pharmaceuticals, Inc.
- Applicants: Rigel Pharmaceuticals, Inc.
- Inventors: Rajinder Singh; Matthew Duncton; Jing Zhang; Salvador Alvarez; Kin Tso; Sacha Holland; Rose Yen; Rao Kolluri; Thilo Heckrodt; Yan Chen; Esteban Masuda; Hui Li; Donald G. Payan
- Web page: https://patentgrep.com/patent/US20140275055A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

## Claims

### Claim 1

A compound of formula (IVc)
wherein
R1, R2, R3, R4, R5, and R6 are independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO2-alkyl, —SO2-substituted alkyl, —SO2-aryl and —SO2-heteroaryl; or R1 and R2 together form an oxo group; or R3 and R4 together form an oxo group; or R5 and R6 together form an oxo group;
R7, R8, R9, and R10 are independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO2-alkyl, —SO2-substituted alkyl, —SO2-aryl and —SO2-heteroaryl; or R7 and R8 together form an oxo group; or R9 and R10 together form an oxo group;
R11 is selected from alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl;
R20 is selected from hydrogen, alkyl, and substituted alkyl;
Y1 and Y2 are independently selected from hydrogen and alkyl; and
R12 is selected from hydrogen and halogen;
R13 and R16 are hydrogen;
R14 is —O-Alk-OR25, where Alk is an optionally substituted alkylene group and R25 is selected from hydrogen and an optionally substituted alkyl group;
R15 is a substituted heterocyclyl;
or a salt or stereoisomer thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R12 is hydrogen.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R12 is fluoro.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R25 is hydrogen.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R25 is an optionally substituted alkyl group.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Alk is a substituted alkylene group.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Alk is an ethylene moiety.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Alk is a substituted ethylene moiety.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R15 is an optionally substituted tetrazolone.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R15 is of the formula
wherein R26 is hydrogen, haloalkyl or alkyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R1 and R2 are hydrogen.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R3 and R4 are hydrogen.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R5 and R6 are hydrogen.

### Claim 14 (depends on 1)

The compound of claim 1, wherein R1, R2, R3, R4, R5, and R6 are hydrogen.

### Claim 15 (depends on 1)

The compound of claim 1, wherein R7, R8, R9, and R10 are independently selected from hydrogen, alkyl, substituted alkyl, and halogen.

### Claim 16 (depends on 1)

The compound of claim 1, wherein R7 and R8 are methyl.

### Claim 17 (depends on 1)

The compound of claim 1, wherein R9 and R10 are hydrogen.

### Claim 18 (depends on 1)

The compound of claim 1, wherein R11 is selected from alkoxy, substituted alkoxy, cyano, halogen, acyl, aminoacyl, and nitro.

### Claim 19 (depends on 1)

The compound of claim 1, wherein R11 is fluoro or cyano.

### Claim 20 (depends on 1)

The compound of claim 1, wherein R20 is hydrogen.

### Claim 21 (depends on 1)

The compound of claim 1, wherein Y1 and Y2 are hydrogen.

### Claim 22 (depends on 1)

The compound of claim 1, wherein the formula is
wherein H1 and H2 are hydrogen with cis relative configuration.

### Claim 23 (depends on 22)

The compound of claim 22, wherein the compound is optically active.

### Claim 24 (depends on 23)

The compound of claim 23, having an enantiomeric excess of 90% or more.

### Claim 25 (depends on 23)

The compound of claim 23, wherein the enantiomeric excess is 95% or more.

### Claim 26 (depends on 23)

The compound of claim 23, wherein the enantiomeric excess is 99% or more.

### Claim 27 (depends on 1)

The compound of claim 1, wherein the compound is selected from:
Compound 77: 1-(2-(2-hydroxyethoxy)-5-(4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluorophenyl)-4-methyl-1H-tetrazol-5(4H)-one;
Compound 78: 4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-2-(4-(2-hydroxyethoxy)-2-fluoro-5-(4,5-dihydro-4-methyl-5-oxotetrazol-1-yl)phenylamino)pyrimidine-5-carbonitrile;
Compound 79: 4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-2-(4-((S)-2-hydroxypropoxy)-2-fluoro-5-(4,5-dihydro-4-methyl-5-oxotetrazol-1-yl)phenylamino)pyrimidine-5-carbonitrile;
Compound 80: 4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-2-(4-(2-hydroxy-2-methylpropoxy)-2-fluoro-5-(4,5-dihydro-4-methyl-5-oxotetrazol-1-yl)phenylamino)pyrimidine-5-carbonitrile;
Compound 81: 1-(2-((S)-2-hydroxypropoxy)-5-(4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluorophenyl)-4-methyl-1H-tetrazol-5(4H)-one;
Compound 82: 1-(5-(4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluoro-2-((R)-2-hydroxypropoxy)phenyl)-4-methyl-1H-tetrazol-5(4H)-one;
Compound 83: 4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-2-(4-(1-hydroxy-2-methylpropan-2-yloxy)-3-(4,5-dihydro-4-methyl-5-oxotetrazol-1-yl)phenylamino)pyrimidine-5-carbonitrile;
Compound 84: 4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-2-(2-fluoro-4-(1-hydroxy-2-methylpropan-2-yloxy)-5-(4-methyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)phenylamino)pyrimidine-5-carbonitrile;
Compound 85: 1-(5-(4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluoro-2-(1-hydroxy-2-methylpropan-2-yloxy)phenyl)-4-methyl-1H-tetrazol-5(4H)-one;
Compound 86: 1-(5-(4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-2-(1-hydroxy-2-methylpropan-2-yloxy)phenyl)-4-methyl-1H-tetrazol-5(4H)-one;
Compound 87: 1-(5-(4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluoro-2-(2-hydroxy-2-methylpropoxy)phenyl)-4-methyl-1H-tetrazol-5(4H)-one; and
Compound 90: 4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-2-(4-((R)-2-hydroxypropoxy)-2-fluoro-5-(4,5-dihydro-4-methyl-5-oxotetrazol-1-yl)phenylamino)pyrimindine-5-carbonitrile.

### Claim 28

A compound selected from:
Compound 88: 1-(5-(4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluoro-2-(oxetan-3-yloxy)phenyl)-4-methyl-1H-tetrazol-5(4H)-one; and
Compound 89: 1-(5-(4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluoro-2-hydroxyphenyl)-4-methyl-1H-tetrazol-5(4H)-one.

### Claim 29 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 30 (depends on 1)

A method of inhibiting a protein kinase C (PKC) activity in a biological sample or a patient, which method comprises contacting the biological sample or administering to the patient a compound of claim 1.
